目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Cancer Type
1.2.3. End use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology Outlook
2.2.2. Test Type Outlook
2.2.3. Cancer Type Outlook
2.2.4. End use Outlook
2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. Minimal Residual Disease Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Minimal Residual Disease Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis

Chapter 4. Minimal Residual Disease Testing Market: Technology Estimates & Trend Analysis
4.1. Technology Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Flow Cytometry
4.4.1.1. Flow Cytometry market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Polymerase Chain Reaction (PCR)
4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Next Generation Sequencing (NGS)
4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Minimal Residual Disease Testing Market: Cancer Type Estimates & Trend Analysis
5.1. Cancer Type Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hematological Malignancy
5.4.1.1. Hematological Malignancy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Leukemia
5.4.1.2.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Lymphoma
5.4.1.3.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Solid Tumors
5.4.2.1. Solid Tumors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Minimal Residual Disease Testing Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global Minimal Residual Disease Testing Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals and Specialty Clinics
6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Academic and Research Institutes
6.4.2.1. Academic and Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Diagnostic Laboratories
6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Others
6.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Minimal Residual Disease Testing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
7.5. North America
7.5.1. North America: SWOT Analysis
7.5.2. U.S.
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Canada
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. Europe: SWOT Analysis
7.6.2. UK
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Germany
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. France
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Italy
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Spain
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Norway
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive scenario
7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Sweden
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework
7.6.8.3. Competitive scenario
7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.9. Denmark
7.6.9.1. Key country dynamics
7.6.9.2. Regulatory framework
7.6.9.3. Competitive scenario
7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific: SWOT Analysis
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. China
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. India
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. Australia
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.7. Thailand
7.7.7.1. Key country dynamics
7.7.7.2. Regulatory framework
7.7.7.3. Competitive scenario
7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Latin America: SWOT Analysis
7.8.2. Brazil
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. MEA: SWOT Analysis
7.9.2. South Africa
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework
7.9.2.3. Competitive scenario
7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework
7.9.3.3. Competitive scenario
7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. UAE
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework
7.9.4.3. Competitive scenario
7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key country dynamics
7.9.5.2. Regulatory framework
7.9.5.3. Competitive scenario
7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Exact Sciences Corporation.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GRAIL, LLC
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Veracyte, Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Natera, Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Guardant Health
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. F. Hoffmann-La Roche Ltd
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. FOUNDATION MEDICINE, INC.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. QIAGEN
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. mdxhealth
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Bio-Techne.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Leading Market Players Anticipated to Witness Highest Growth
Table 4 Global Minimal Residual Disease Testing Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 6 Global Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 7 Global Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 8 North America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 10 North America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 11 North America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 12 U.S Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 13 U.S Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 14 U.S Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 15 Canada Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 16 Canada Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 17 Canada Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 18 Mexico Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 19 Mexico Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 20 Mexico Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 21 Europe Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 22 Europe Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 23 Europe Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 24 Europe Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 25 UK Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 26 UK Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 27 UK Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 28 Germany Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 29 Germany Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 30 Germany Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 31 France Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 32 France Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 33 France Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 34 Italy Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 35 Italy Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 36 Italy Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 37 Spain Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 38 Spain Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 39 Spain Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 40 Denmark Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 41 Denmark Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 42 Denmark Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 43 Sweden Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 44 Sweden Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 45 Sweden Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 46 Norway Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 47 Norway Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 48 Norway Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 52 Asia Pacific Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 53 Japan Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 54 Japan Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 55 Japan Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 56 China Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 57 China Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 58 China Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 59 India Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 60 India Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 61 India Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 62 South Korea Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 63 South Korea Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 64 South Korea Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 65 Australia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 66 Australia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 67 Australia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 68 Thailand Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 69 Thailand Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 70 Thailand Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 71 Latin America Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 72 Latin America Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 73 Latin America Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 74 Latin America Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 75 Brazil Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 76 Brazil Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 77 Brazil Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 78 Argentina Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 79 Argentina Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 80 Argentina Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 81 Middle East and Africa Minimal Residual Disease Testing Market, By Country, 2018 - 2030 (USD Million)
Table 82 Middle East and Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 83 Middle East and Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 84 Middle East & Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 85 South Africa Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 86 South Africa Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 87 South Africa Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 91 UAE Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 92 UAE Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 93 UAE Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 94 Kuwait Minimal Residual Disease Testing Market, By Technology, 2018 - 2030 (USD Million)
Table 95 Kuwait Minimal Residual Disease Testing Market, By Cancer Type, 2018 - 2030 (USD Million)
Table 96 Kuwait Minimal Residual Disease Testing Market, By End Use, 2018 - 2030 (USD Million)Abbreviations

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Minimal Residual Disease Testing: market outlook
Fig. 14 Minimal Residual Disease Testing competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook.
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Minimal Residual Disease Testing driver impact
Fig. 20 Minimal Residual Disease Testing restraint impact
Fig. 21 Minimal Residual Disease Testing strategic initiatives analysis
Fig. 22 Minimal Residual Disease Testing: Technology movement analysis
Fig. 23 Minimal Residual Disease Testing: Technology outlook and key takeaways
Fig. 24 Flow Cytometry market estimates and forecast, 2018 - 2030 USD Million
Fig. 25 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 USD Million
Fig. 26 Next Generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 USD Million
Fig. 27 Others market estimates and forecast, 2018 - 2030 USD Million
Fig. 28 Minimal Residual Disease Testing: Cancer movement analysis
Fig. 29 Minimal Residual Disease Testing: Cancer outlook and key takeaways
Fig. 30 Hematological Malignancy market estimates and forecast, 2018 - 2030 USD Million
Fig. 31 Leukemia market estimates and forecast, 2018 - 2030 USD Million
Fig. 32 Lymphoma market estimates and forecast, 2018 - 2030 USD Million
Fig. 33 Solid Tumors market estimates and forecast, 2018 - 2030 USD Million
Fig. 34 Minimal Residual Disease Testing: End use movement analysis
Fig. 35 Minimal Residual Disease Testing: End use outlook and key takeaways
Fig. 36 Hospitals & Specialty Clinics market estimates and forecast, 2018 - 2030 USD Million
Fig. 37 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 USD Million
Fig. 38 Academic and Research Institutions market estimates and forecast, 2018 - 2030 USD Million
Fig. 39 Others market estimates and forecast, 2018 - 2030 USD Million
Fig. 40 Global minimal residual disease testing market: Regional movement analysis
Fig. 41 Global minimal residual disease testing market: Regional outlook and key takeaways
Fig. 42 Global minimal residual disease testing market shares and leading players
Fig. 43 North America
Fig. 44 North America market estimates and forecast, 2018 - 2030 USD Million
Fig. 45 U.S.
Fig. 46 U.S. market estimates and forecast, 2018 - 2030 USD Million
Fig. 47 Canada
Fig. 48 Canada market estimates and forecast, 2018 - 2030 USD Million
Fig. 49 Mexico
Fig. 50 Mexico market estimates and forecast, 2018 - 2030 USD Million
Fig. 51 Europe
Fig. 52 Europe market estimates and forecast, 2018 - 2030 USD Million
Fig. 53 UK
Fig. 54 UK market estimates and forecast, 2018 - 2030 USD Million
Fig. 55 Germany
Fig. 56 Germany market estimates and forecast, 2018 - 2030 USD Million
Fig. 57 France
Fig. 58 France market estimates and forecast, 2018 - 2030 USD Million
Fig. 59 Italy
Fig. 60 Italy market estimates and forecast, 2018 - 2030 USD Million
Fig. 61 Spain
Fig. 62 Spain market estimates and forecast, 2018 - 2030 USD Million
Fig. 63 Denmark
Fig. 64 Denmark market estimates and forecast, 2018 - 2030 USD Million
Fig. 66 Sweden
Fig. 67 Sweden market estimates and forecast, 2018 - 2030 USD Million
Fig. 68 Norway
Fig. 69 Norway market estimates and forecast, 2018 - 2030 USD Million
Fig. 70 Asia Pacific
Fig. 71 Asia Pacific market estimates and forecast, 2018 - 2030 USD Million
Fig. 72 China
Fig. 73 China market estimates and forecast, 2018 - 2030 USD Million
Fig. 74 Japan
Fig. 75 Japan market estimates and forecast, 2018 - 2030 USD Million
Fig. 76 India
Fig. 77 India market estimates and forecast, 2018 - 2030 USD Million
Fig. 79 Thailand
Fig. 80 Thailand market estimates and forecast, 2018 - 2030 USD Million
Fig. 81 South Korea
Fig. 82 South Korea market estimates and forecast, 2018 - 2030 USD Million
Fig. 83 Australia
Fig. 84 Australia market estimates and forecast, 2018 - 2030 USD Million
Fig. 85 Latin America
Fig. 86 Latin America market estimates and forecast, 2018 - 2030 USD Million
Fig. 87 Brazil
Fig. 88 Brazil market estimates and forecast, 2018 - 2030 USD Million
Fig. 89 Argentina
Fig. 90 Argentina market estimates and forecast, 2018 - 2030 USD Million
Fig. 91 Middle East and Africa
Fig. 92 Middle East and Africa market estimates and forecast, 2018 - 2030 USD Million
Fig. 93 South Africa
Fig. 94 South Africa market estimates and forecast, 2018 - 2030 USD Million
Fig. 95 Saudi Arabia
Fig. 96 Saudi Arabia market estimates and forecast, 2018 - 2030 USD Million
Fig. 97 UAE
Fig. 98 UAE market estimates and forecast, 2018 - 2030 USD Million
Fig. 99 Kuwait
Fig. 100 Kuwait market estimates and forecast, 2018 - 2030 USD Million
Fig. 101 Market share of key market players- Minimal Residual Disease Testing